百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

未开盘 12-23 16:08:09

184.000

-2.600

-1.39%

最高188.900	最低183.400	成交量183.28万
今开186.600	昨收186.600	日振幅2.95%
总市值2,835亿	流通市值2,624亿	总股本15.41亿
成交额3.39亿	换手率0.13%	流通股本14.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":184,"timestamp":1766477289009,"preClose":186.6,"halted":0,"volume":1832768,"delay":0,"floatShares":1426000000,"shares":1541000000,"eps":-3.6636957536164254,"marketStatus":"未开盘","change":-2.6,"latestTime":"12-23 16:08:09","open":186.6,"high":188.9,"low":183.4,"amount":339377165,"amplitude":0.029475,"askPrice":184.1,"askSize":8700,"bidPrice":184,"bidSize":3700,"shortable":3,"etf":0,"ttmEps":0.3498055685176544,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":0,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":186.6,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"volumeRatio":0.5989173680011274,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":276.83,"timestamp":1766473200000,"preClose":274.3,"halted":0,"volume":1486000,"delay":0,"premium":"-40.01"}},"requestUrl":"/m/hq/s/06160/tweets","defaultTab":"tweets","newsList":[{"id":"2593741940","title":"12月，石药集团、百济神州、百花村医药等一批药企已“换帅”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593741940","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593741940?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:17","pubTimestamp":1766474250,"startTime":"0","endTime":"0","summary":"如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月19日，石药集团公告宣布执行董事蔡磊接任董事会副主席、首席执行官。12月12日，药明巨诺发布公告，宣布一系列核心管理层及董事会架构调整。除了上述企业，在12月以来，恒瑞医药、康恩贝、南新制药、振东制药等也已发布过高管变动公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","IE0008369823.USD","LU1951186391.HKD","LU0307460666.USD","IE00BZ08YS42.EUR","LU2543165471.USD","LU1023057109.AUD","IE00B5MMRT66.SGD","09939","LU0588546209.SGD","LU1008478684.HKD","LU1226287529.USD","LU1813983027.USD","LU1960683339.HKD","LU1152091168.USD","BK1161","IE00B543WZ88.USD","01093","LU0880133367.SGD","LU0315179316.USD","BK1191","LU0140636845.USD","LU0501845795.SGD","LU1719994722.HKD","LU2328871848.SGD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU0359202008.SGD","LU1969619763.USD","HK0000165453.HKD","LU1226288170.HKD","BK1583","IE00BZ08YT58.USD","06160","LU1328277881.USD","01276","LU0067412154.USD","LU0314109678.HKD","LU0359201885.HKD","LU0072913022.USD","LU1152091754.HKD","LU1993786604.SGD","BK1500","LU1807302812.USD","LU2039709279.SGD","BK1515","SG9999004220.SGD","LU0359201612.USD","BK1588","IE00B031HY20.USD"],"gpt_icon":0},{"id":"2593456295","title":"智通港股通资金流向统计(T+2)|12月23日","url":"https://stock-news.laohu8.com/highlight/detail?id=2593456295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593456295?lang=zh_cn&edition=full","pubTime":"2025-12-23 07:31","pubTimestamp":1766446262,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月18日,小米集团-W、美团-W、长飞光纤光缆南向资金净流入金额位列市场前三，分别净流入9.04 亿、4.76 亿、3.56 亿盈富基金、中国移动、信达生物南向资金净流出金额位列市场前三，分别净流出-14.20 亿、-12.95 亿、-2.71 亿在净流入比方面，南方恒指ETF、工银南方中国、美的置业以84.61%、75.00%、65.00%位列市场前三。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00386","03868","00857","89988","01952","00272","01801","00388","01810","HKXCY","02899","03037","02318","00006","03145","ALBmain","02328","03968","09985","82318","00107","03167","09899","HEXmain","01186","00016","01117","00003","01288","03690","06098","03328","00363","HMTD.SI","03121","00941","01093","06869","06160","01258","01686","PAImain","PNGAY","81810","03990","03442","03143","02800"],"gpt_icon":1},{"id":"2593714185","title":"百济神州刚赚钱就开始搞事情了","url":"https://stock-news.laohu8.com/highlight/detail?id=2593714185","media":"财报时间","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593714185?lang=zh_cn&edition=full","pubTime":"2025-12-20 08:30","pubTimestamp":1766190632,"startTime":"0","endTime":"0","summary":"2025年前三季度，百济神州营收275.95亿元，净利润11.39亿元，公司成立以来头一次赚钱。要理解百济神州为什么能赚钱，绕不开泽布替尼这款药。根据百济神州财报，2024年泽布替尼全球卖了26亿美元，进了全球重磅药物百强榜。收入增长的同时，百济神州花钱的效率也在提高。百济神州的应对策略是继续推新药。在法律层面，百济神州刚刚扫清了一个障碍。2023年，艾伯维旗下公司起诉百济神州专利侵权，官司打了两年多。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220084003a6b8f60d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220084003a6b8f60d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU1770034418.SGD","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0307460666.USD","LU0588546209.SGD","LU1251922891.USD","LU1719994722.HKD","BK1500","BK1588","06160","LU1303224171.USD"],"gpt_icon":1},{"id":"2593868141","title":"百济神州有限公司使用新信贷资金偿还并终止招商银行授信协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2593868141","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593868141?lang=zh_cn&edition=full","pubTime":"2025-12-20 01:40","pubTimestamp":1766166000,"startTime":"0","endTime":"0","summary":"中访网数据百济神州有限公司于2025年12月16日宣布，已动用其近期与汇丰银行等金融机构签署的新《授信协议》项下所获的部分贷款资金，全额偿还了其与招商银行股份有限公司于2024年12月9日签订的原有授信协议项下的所有借款。此次偿还同时终止了招商银行在该协议项下提供的所有进一步授信承诺，并解除了公司就该协议向招商银行提供的所有担保及担保权益。公司强调，此次提前终止招行信贷协议并未产生任何终止罚款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220014023a460fe22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220014023a460fe22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348816934.USD","LU1719994722.HKD","LU0314109678.HKD","LU0516422440.USD","LU0052750758.USD","LU1960683339.HKD","BK1161","LU0287142896.SGD","LU0543330566.HKD","IE00B3M56506.USD","LU0488056044.USD","LU0648948544.HKD","LU0880133367.SGD","SG9999002463.SGD","LU0868486357.SGD","LU0359201612.USD","LU1807302812.USD","LU1008478684.HKD","LU0737861699.HKD","LU0516422952.EUR","LU0589944569.HKD","LU1770034418.SGD","LU1188198961.HKD","03968","LU0067412154.USD","LU1242518931.SGD","LU0348825331.USD","BK1231","LU0106959298.USD","03143","LU0231483743.USD","LU0417516738.SGD","LU0456846285.SGD","LU0634319403.HKD","LU0228367735.SGD","LU1023057109.AUD","LU0463099449.HKD","LU0455707207.USD","LU1282649810.SGD","LU0540923850.HKD","06160","BK1560","LU2476274308.USD","LU0823426480.USD","LU0348827113.USD","LU0561508036.HKD","LU0588546209.SGD","LU1328277881.USD","LU1880383366.USD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2592959471","title":"双总裁时代的百济神州 还有哪些故事可讲？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592959471","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592959471?lang=zh_cn&edition=full","pubTime":"2025-12-19 23:31","pubTimestamp":1766158317,"startTime":"0","endTime":"0","summary":"12月19日，百济神州迎来新的人事调整。百济神州发布公告称，公司董事会同意聘任全球研发负责人汪来博士担任百济神州总裁，全球研发负责人。聘任生效后，汪来将担任百济神州总裁，全球研发负责人职务，负责管理百济神州研发、业务拓展以及业务联盟关系管理等职能。此外，百济神州方面还透露，吴晓滨仍然担任百济神州总裁、首席运营官COO，与汪来并列为双总裁。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193597095415.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193597095415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1719994722.HKD","LU2328871848.SGD","BK1161","BK1588","LU1303224171.USD","LU0307460666.USD","BK4585","LU1770034418.SGD","BK1583","688235","BK4139","BK4526","BK1500","ONC","BK0239","06160","LU1969619763.USD","LU0588546209.SGD","LU1251922891.USD"],"gpt_icon":0},{"id":"2592162940","title":"智通港股解盘 | 海南自贸港封关意义重大 无人驾驶利好密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592162940?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:58","pubTimestamp":1766149121,"startTime":"0","endTime":"0","summary":"海南自由贸易港昨天正式启动全岛封关，8个对外开放口岸及10个“二线口岸”监管设施全部启用。标志着3万多平方公里的海南岛正式成为海关监管特殊区域，中国对外开放迎来具有里程碑意义的标志性举措。回购的H股股份将作为库存股持有，并在完成回购并披露回购结果公告后三年内完成转让或注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","BK1179","06821","LU0516423091.SGD","01318","02431","03759","01880","601995","BK1163","02039","02050","00699","BK1564","LU1719994722.HKD","LU2328871848.SGD","LU0307460666.USD","03908","BK1539","LU0819121731.USD","LU1880383366.USD","LU2039709279.SGD","01057","LU0417516902.SGD","01316","BK1500","LU0181495838.USD","06160","LU0348735423.USD","01999","02498","LU1794554557.SGD","02269","09868","BK1183","LU1969619763.USD","BK1589","LU0455707207.USD","BK1583","LU0348766576.USD","BK1224","LU1580142542.USD","09863","02533","SG9999002463.SGD","BK1191","BK1521","LU0593848301.USD"],"gpt_icon":1},{"id":"2592150459","title":"百济神州（688235）披露聘任公司高级管理人员公告，12月19日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150459","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592150459?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:43","pubTimestamp":1766137421,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，百济神州报收于274.0元，较前一交易日上涨0.86%，最新总市值为4221.46亿元。该股当日开盘272.0元，最高274.88元，最低269.79元，成交额达4.9亿元，换手率为1.56%。公司近日发布公告称，2025年12月17日，经公司董事会审议通过，聘任汪来博士担任百济神州有限公司总裁、全球研发负责人，负责管理公司研发、业务拓展及业务联盟关系管理等职能。汪来博士自2011年加入公司，曾任多个研发领导职务，2021年4月起任全球研发负责人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900027078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1303224171.USD","BK1588","06160","LU1969619763.USD","BK1500","LU1770034418.SGD","BK0239","LU0588546209.SGD","LU1719994722.HKD","BK1161","LU0307460666.USD","LU1251922891.USD","LU2328871848.SGD","688235","BK1583"],"gpt_icon":0},{"id":"2592513686","title":"【券商聚焦】交银国际：临近年末 续看好新BD交易集中落地机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2592513686","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592513686?lang=zh_cn&edition=full","pubTime":"2025-12-19 09:20","pubTimestamp":1766107245,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，本周多项超10亿美元的BD交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，该机构继续看好新BD交易集中落地机会。展望2026 年，该机构认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势，后续选股逻辑或将重回基本面和估值，即关注存在基本面预期差、当前仍被低估的个股。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971853","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","09926","BK1191","03329","IE00B543WZ88.USD","LU2399975544.HKD","SG9999014674.SGD","LU0634319403.HKD","LU1720050803.USD","BK1500","01530","LU1794554557.SGD","03933","LU0348784397.USD","LU1115378108.SGD","LU1770034418.SGD","LU2476274308.USD","BK1588","06160","BK1585","LU1303224171.USD","BK1197","BK1583","BK1617","02196","02228","09688","LU0348825331.USD","02367","HK0000165453.HKD","LU0348735423.USD","01789","BK1593","LU0348766576.USD","LU0417516738.SGD","LU0540923850.HKD","LU0561508036.HKD","LU2488822045.USD","02268","BK1147","LU2778985437.USD","LU0417516902.SGD","LU0307460666.USD","LU2328871848.SGD","LU2476274720.SGD","LU1251922891.USD","01099","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348783233.USD"],"gpt_icon":0},{"id":"2592836189","title":"百济神州聘任公司全球研发负责人汪来担任公司总裁，全球研发负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2592836189","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592836189?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":"百济神州发布公告，2025年12月17日，经百济神州有限公司董事会审议通过，公司董事会同意聘任公司全球研发负责人汪来博士担任公司总裁，全球研发负责人。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218203158a6b29ed9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218203158a6b29ed9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1719994722.HKD","LU1969619763.USD","BK1588","LU1770034418.SGD","06160","LU1251922891.USD","LU2328871848.SGD","BK1500","LU1303224171.USD","BK1161","LU0588546209.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2592918983","title":"每日卖空追踪 | 百济神州 12月18日卖空量成交27.01万股，卖空比例为8.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918983","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592918983?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:30","pubTimestamp":1766046634,"startTime":"0","endTime":"0","summary":"百济神州北京时间12月18日，涨1.1%，卖空量成交27.01万股，较上一交易日减少30.71%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163545a6b1b5cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163545a6b1b5cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","LU2328871848.SGD","BK1588","LU1251922891.USD","LU1719994722.HKD","LU0307460666.USD","LU1969619763.USD","LU0588546209.SGD","LU1770034418.SGD","LU1303224171.USD","06160","BK1500"],"gpt_icon":0},{"id":"2591022646","title":"东方财富证券：创新浪潮涌动下 关注医药板块修复与突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2591022646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591022646?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:25","pubTimestamp":1765873557,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方财富证券发布研报称，随着中国创新药License-out项目总金额创下新纪录，临床前项目占比持续保持高位，ADC、双/多抗、小核酸等新兴疗法，以及代谢领域中肥胖适应症等或为未来License-out项目的重点方向。东方财富证券主要观点如下：今年以来，在创新药、AI医疗的带动下，化学制药板块领涨医药板块估值水平接近最近10年历史平均水平。中国创新药十年变革主要得益于全面的监管改革、研发投入的增加以及战略性的全球化布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","LU2495084118.USD","BK0196","LU1831875114.USD","09939","BK1589","LU2097828557.USD","BK0028","300059","SG9999014674.SGD","LU2543165471.USD","LU1303224171.USD","LU1770034418.SGD","LU1997244956.HKD","161027","LU0326950275.SGD","BK0095","BK1515","LU0588546209.SGD","LU1251922891.USD","BK1500","LU2097828714.EUR","LU1997245177.USD","LU0307460666.USD","159938","BK1583","IE00BZ08YS42.EUR","01177","LU2097828631.EUR","HK0000165453.HKD","BK1521","BK0188","06160","01276","LU2328871848.SGD","LU2580892789.USD","BK1191","BK1588","LU1719994722.HKD","LU2097828474.EUR","IE00BZ08YR35.GBP","LU0359202008.SGD","IE00BZ08YT58.USD","BK0077","LU2289578879.USD","BK1574","LU2097828805.USD"],"gpt_icon":0},{"id":"2591986748","title":"百济神州12月16日获主力加仓1838.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591986748","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591986748?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:15","pubTimestamp":1765872944,"startTime":"0","endTime":"0","summary":"12月16日, 百济神州股价涨1.40%，报收181.30元，成交金额7.4亿元，换手率0.29%，振幅4.14%，量比0.94。百济神州今日主力资金净流入1838.2万元，上一交易日主力净流入1.1亿元。|12月16日主力加仓幅度排名||#|股票简称|主力净额占比|#|嘉艺控股|4.42%|#|同景新能源|1.95%|#|汇舸环保|0.94%|#|...|...|#284|百济神州|0.01%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216161944a4518d98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216161944a4518d98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1251922891.USD","BK1500","LU2328871848.SGD","BK1588","LU0588546209.SGD","LU0307460666.USD","LU1719994722.HKD","LU1969619763.USD","BK1161","06160","LU1303224171.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2591935320","title":"深度研究报告|创新药出海潮起：恒瑞医药、百济神州领航","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935320","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591935320?lang=zh_cn&edition=full","pubTime":"2025-12-16 13:21","pubTimestamp":1765862507,"startTime":"0","endTime":"0","summary":"▲ 定档2026年5月29-30日苏州！精益智造·链接全球：2026中国制药产业大会重磅官宣！●如需获取完整版报告，关注“药视声”并回复“出海”，即可获得！文章来源：东吴证券研究所","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216132749a6a809cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216132749a6a809cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1770034418.SGD","LU1969619763.USD","LU1303224171.USD","LU0359202008.SGD","LU0307460666.USD","LU2543165471.USD","BK1500","LU1251922891.USD","BK1191","BK1588","BK1574","LU0359201612.USD","01276","06160","LU1719994722.HKD","LU2328871848.SGD","LU1023057109.AUD","LU0359201885.HKD","BK1583","LU0588546209.SGD","BK1161","06978"],"gpt_icon":0},{"id":"2591376935","title":"TIGIT抗体再折戟：胃癌三期失败，免疫治疗前路何在？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591376935","media":"药事纵横","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591376935?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:03","pubTimestamp":1765839790,"startTime":"0","endTime":"0","summary":"2025年12月12日，吉利德与Arcus Biosciences联合宣布，其PD-1+TIGIT+化疗一线治疗胃癌的三期临床STAR-221因无效而终止。这是TIGIT抗体赛道又一次重大挫折，也再次引发业界对免疫联合疗法靶点选择与临床策略的深刻反思。PD-1/TIGIT双抗可以同时阻断这两条免疫逃逸通路，恢复T细胞和NK细胞的活性，产生更强的抗肿瘤免疫反应 。PD-1/TIGIT双抗若能在临床试验中取得成功，将有望填补肿瘤免疫治疗领域的空白，满足未被满足的临床需求，市场潜力巨大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1770034418.SGD","ONC","LU1719994722.HKD","BK1588","BK1500","BK1583","06160","LU0588546209.SGD","LU1969619763.USD","BK1161","LU1303224171.USD","LU1251922891.USD","LU0307460666.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591602930","title":"医药行业2026年年度策略报告：从“治疗领域”和“技术平台”双管齐下挖掘创新龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2591602930","media":"平安证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591602930?lang=zh_cn&edition=full","pubTime":"2025-12-16 00:00","pubTimestamp":1765814400,"startTime":"0","endTime":"0","summary":"CXO 和上游：行业环境方面，医药融资小幅增长，BD 交易、H 股IPO 回暖等因素激活创新热情，订单端呈现回暖态势。投资思路上，外向型CXO整体需求增长，可关注提前布局多肽、小核酸、ADC 等新兴领域的公司。内向型CXO 订单端回暖，建议重点关注SMO、临床前CRO 等领域的公司。建议关注迈瑞医疗、新产业、惠泰医疗、微电生理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216133627a450f8ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216133627a450f8ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01167","06160","BK1574"],"gpt_icon":0},{"id":"2591462139","title":"每日卖空追踪 | 百济神州 12月15日卖空量成交40.41万股，卖空比例为5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591462139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591462139?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787435,"startTime":"0","endTime":"0","summary":"百济神州北京时间12月15日，跌8.07%，卖空量成交40.41万股，较上一交易日减少36.03%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163549a6a45937&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163549a6a45937&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","LU1303224171.USD","LU2328871848.SGD","LU1719994722.HKD","BK1500","06160","BK1583","LU1969619763.USD","LU1770034418.SGD","BK1161","BK1588","LU1251922891.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2591697904","title":"午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697904","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591697904?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:39","pubTimestamp":1765777140,"startTime":"0","endTime":"0","summary":"12月15日午后，港股通创新药板块加速下跌，港股通创新药ETF一度跌至2.77%创近5个月新低，龙头股齐挫，康方生物跌超5%，百济神州跌逾6%，中国生物制药、信达生物跌超3%。　　阶段新低之际，“抄底”资金或再行动，港股通创新药ETF场内宽幅溢价，显示买盘资金相对强势。　　把握港股创新药低吸窗口期，认准同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-15/doc-inhawauf3976382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348766576.USD","LU0417516902.SGD","09926","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516571.SGD","BK1161","BK1583","LU0588546209.SGD","BK4139","520880","LU0634319403.HKD","06160","LU1770034418.SGD","LU2476274308.USD","BK1588","LU0540923850.HKD","BK4526","BK4585","IE00B543WZ88.USD","LU0348825331.USD","LU0348783233.USD","LU1251922891.USD","LU1303224171.USD","LU1969619763.USD","LU1794554557.SGD","LU0561508036.HKD","LU1961090484.USD","688235","IE00BPRC5H50.USD","LU2399975544.HKD","LU2476274720.SGD","LU1719994722.HKD","LU1720050803.USD","LU0307460666.USD","LU2328871848.SGD","LU2488822045.USD","BK0239","LU2778985437.USD","BK1500","LU0417516738.SGD","BK1574","LU0348784397.USD","LU0348735423.USD","LU0348827113.USD","ONC"],"gpt_icon":0},{"id":"2591691376","title":"恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591691376?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:11","pubTimestamp":1765768311,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒生医疗保健指数跌幅扩大至2.75%，医药股普遍走低，科伦博泰生物(06990)跌7.07%，百济神州(06160)跌5.35%，复宏汉霖(02696)跌5.32%，荣昌生物(09995)跌4.05%，康方生物(09926)跌3.61%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU0417516738.SGD","06990","LU2778985437.USD","BK1588","09926","LU2328871848.SGD","LU0348767384.USD","LU1770034418.SGD","09995","09939","LU0348784397.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU1961090484.USD","LU2476274308.USD","02696","LU0307460666.USD","LU0417516902.SGD","BK1500","LU1251922891.USD","LU2399975544.HKD","06160","159506","BK1574","LU0561508036.HKD","LU0348783233.USD","LU0634319403.HKD","LU0348825331.USD","LU0196878994.USD","LU1969619763.USD","LU0417516571.SGD","BK1515","LU1303224171.USD","LU0348735423.USD","BK1583","LU0348766576.USD","159938","LU2488822045.USD","BK1161","LU1720050803.USD","LU1794554557.SGD","LU1719994722.HKD","LU2476274720.SGD","LU0588546209.SGD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2591640278","title":"医药行业周报：医药板块逐步筑底","url":"https://stock-news.laohu8.com/highlight/detail?id=2591640278","media":"西南证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591640278?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:06","pubTimestamp":1765764387,"startTime":"0","endTime":"0","summary":"投资要点行情回顾：本周医药生物指数下跌1.04%，跑输沪深300指数0.96个百分点，行业涨跌幅排名第18。中央经济工作会议12月10日至11日在北京举行，首次明确提出优化药品集中采购，深化医保支付方式改革。药品在原集采最低价中标基础上优化，叠加药品支付端改善，医药商业化空间或将进一步扩大。本次集采共纳入55种药品，中标率57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215100647a6a30153&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215100647a6a30153&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","BK1574","BK1500","BK1588","06160","LU0307460666.USD","BK1161","LU2328871848.SGD","LU1303224171.USD","LU1770034418.SGD","LU1969619763.USD","09939","BK1515","BK1583","LU1719994722.HKD","LU1251922891.USD"],"gpt_icon":0},{"id":"2591015695","title":"千亿市值创新药企俱乐部扩容！百济神州、百利天恒、信达生物等强势崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2591015695","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591015695?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:51","pubTimestamp":1765763499,"startTime":"0","endTime":"0","summary":"根据数据统计，截至11月19日，A股和港股的千亿市值创新药企俱乐部已扩容至8家。其中，百济神州A股总市值超过4000亿元，百利天恒总市值超过1500亿元。港股千亿市值俱乐部包括百济神州、翰森制药、信达生物、康方生物等。其中，总市值超4000亿元的创新药企业百济神州已连续两个季度实现盈利。据悉，在研发方面，百济神州的研发管线也进入集中兑现阶段，未来18个月将迎来20项关键里程碑事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU0588546209.SGD","06160","LU2328871848.SGD","BK1574","BK1589","LU1719994722.HKD","LU2097828631.EUR","LU0307460666.USD","06978","BK1500","02615","HK0000165453.HKD","LU2097828805.USD","LU2488822045.USD","LU1303224171.USD","91194","03692","LU2097828714.EUR","LU1770034418.SGD","LU2097828557.USD","LU2242644610.SGD","BK1161","BK1588","LU1251922891.USD","LU0455707207.USD","LU0502904849.HKD","01801","LU1969619763.USD","LU2097828474.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":-0.1068},{"period":"3month","weight":-0.0646},{"period":"6month","weight":0.1337},{"period":"1year","weight":0.7342},{"period":"ytd","weight":0.685}],"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.0281},{"period":"6month","weight":0.0596},{"period":"1year","weight":0.2963},{"period":"ytd","weight":0.2849}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.052709},{"month":6,"riseRate":0.428571,"avgChangeRate":0.007027},{"month":7,"riseRate":0.857143,"avgChangeRate":0.097108},{"month":8,"riseRate":0.857143,"avgChangeRate":0.058603},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.072901}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}